Control of Helicobacter Pylori Infection by Probiotics
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01115296|
Recruitment Status : Unknown
Verified August 2012 by Ruggiero Francavilla, University of Bari.
Recruitment status was: Recruiting
First Posted : May 4, 2010
Last Update Posted : August 17, 2012
Helicobacter pylori colonises an estimated 50% of the world´s population (Taylor & Blaser, 1991; Go, 2002). Despite clear clinical guidelines on the treatment of this infection (Malfertheiner et al. 2007) there is a drive to find alternative ways to control this infection in a wider perspective without the complications of induction of antibiotic resistance in the pathogen.
L. reuteri has been widely studied in clinical trials and has been shown to have probiotic, health-promoting effects in both adults and children (Connolly 2004; Casas & Dobrogosz, 2000). L. reuteri has been shown in numerous studies to be safe for human consumption and it has been shown to colonise the human gastrointestinal tract (Wolf et al., 1995, Valeur et al., 2004).
Studies using supplementation with L. reuteri in both symptomatic and non-symptomatic H. pylori-infected subjects show a clear reduction of infection load after 4 weeks of use and this was concomitant with a reduction in symptoms associated with the infection (Imase et al. 2007; Francavilla et al. 2007, unpublished data). Further, dietary supplementation with L. reuteri during and after the period of H. pylori eradication therapy has also been shown to reduce the side effects of this therapy without affecting the degree of eradication (Lionetti et al., 2007). It is also feasible, through the inhibitory action of L. reuteri on H. pylori, that pre-exposure to L. reuteri may weaken H. pylori and make it more susceptible to antibiotic attack during eradication.
However, an earlier pilot study was not been able to demonstrate a reduction in gastric inflammation caused by H. pylori. This pilot study was performed with L. reuteri ATCC 55730 that has since been found to lack anti-inflammatory activity in in vitro screens. Recent selection of natural, human L. reuteri strains has identified a specific strain with strong anti-inflammatory properties in vitro (Lin et al, 2007 and submitted 2007). A combination of this strain, together with the earlier proven L. reuteri strain, is expected to lead to both a reduction of H. pylori load as well as a reduction in the gastric inflammation related to the pathogen.
|Condition or disease||Intervention/treatment||Phase|
|Helicobacter Pylori Infection||Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475 Other: Placebo||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Control of Helicobacter Pylori Infection by Dietary Supplementation With Lactobacillus Reuteri|
|Study Start Date :||January 2010|
|Estimated Primary Completion Date :||August 2012|
|Estimated Study Completion Date :||August 2012|
Active Comparator: 'L. reuteri DSM 17938 and ATCC PTA 6475
L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.
Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475
L. reuteri dose of 1x108 CFU.
Other Name: Probiotic mixture
Placebo Comparator: Placebo
Other Name: Placebo identical to active
- to decrease H. pylori gastric load [ Time Frame: 28 days ]
Primary Outcome Measures:
Decrease H. pylori gastric load by histology after 28 days compared to placebo and by 13C-UBT compared to placebo.
- To decrease dyspeptic symptoms [ Time Frame: 28 days ]To decrease dyspeptic symptoms before, during and after eradication therapy as assessed by a gastro-intestinal symptom rating scale
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01115296
|Contact: Ruggiero Francavilla, MD, PhD||+390805592063 ext firstname.lastname@example.org|
|Unit of Gastroenterology||Recruiting|
|Bari, Italy, 70100|
|Contact: Beatrice Principi, MD +390805592869|
|Principal Investigator:||Principi Beatrice, MD||University of Bari|